parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in respiratory basal cells	0.75
chemistry Open Targets	compounds already reach it: etokimab, torudokimab, itepekimab	0.81
trials ClinicalTrials.gov	1 Parkinson's trial, 1 stopped	0.20
literature PubMed	21 Parkinson's papers of 6,625	0.59
pathways Reactome	4 pathways; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 5359

receipt 5367: IL33 in dopamine neurons, braak

power: full sample +0.09 (p 0.728, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.652, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.609, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.21, sign flips 3; without severely affected donors +0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IL33 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5366: IL33 in astrocytes, braak

power: full sample +0.25 (p 0.310, n 18), 95% CI -0.24 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.24 (p 0.346, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.25 (p 0.310, n 18). could be the mix.
skeptic: leave-one-out range +0.15 to +0.38, sign flips 0; without severely affected donors +0.25 (p 0.310, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for IL33 in astrocytes.

case closed: nothing better to follow up.

loading the receipts